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Abstract
Background: Pneumococcal meningitis (PM) is a major invasive pneumococcal disease. Two pneumococcal
conjugate vaccines (PCVs) have been introduced in France: PCV7 was recommended in 2003 and replaced in
2010 by PCV13, which has six additional serotypes. The impact of introducing those vaccines on the evolution
of PM case numbers and serotype distributions in France from 2001 to 2014 is assessed herein.
Methods: Data on 5166 Streptococcus pneumoniae strains isolated from cerebrospinal fluid between 2001 and
2014 in the 22 regions of France were obtained from the National Reference Center for Pneumococci. The
effects of the different vaccination campaigns were estimated using time series analyses through autoregressive
moving-average models with exogenous variables (“flu-like” syndromes incidence) and intervention functions.
Intervention functions used 11 dummy variables representing each post vaccine epidemiological period. The
evolution of serotype distributions was assessed for the entire population and the two most exposed age
groups (<5 and > 64 years old).
Results: For the first time since PCV7 introduction in 2003, total PM cases decreased significantly after starting PCV13
use: –7.1 (95% CI, –10.85 to –3.35) cases per month during 2013–2014, and was confirmed in children < 5 years old
(–3.5; 95% CI, –4.81 to –2.13) and adults > 64 years old (–2.0; 95% CI, –3.36 to –0.57). During 2012–2014, different non-
vaccine serotypes emerged: 12F, 24F in the entire population and children, 6C in the elderly; serotypes 3 and 19F
persisted in the entire population.
Conclusions: Unlike other European countries, the total PM cases in France declined only after introduction of PCV13.
This suggests that vaccine pressure alone does not explain pneumococcal epidemiological changes and that other
factors could play a role. Serotype distribution had changed substantially compared to the pre-vaccine era, as in other
European countries, but very differently from the US. A highly reactive surveillance system is thus necessary not
only to monitor evolutions due to vaccine pressure and to verify the local serotypic appropriateness of new
higher-valent pneumococcal vaccines, but also to recognise and prevent unexpected changes due to other
internal or external factors.
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Background
Streptococcus pneumoniae, a Gram-positive commensal
bacterium of the nasopharynx, usually colonises the re-
spiratory tract or nasal cavity. It can cause non-invasive
community diseases (i.e. otitis media and sinusitis),
invasive pneumococcal diseases (IPDs, i.e. meningitis,
bacteraemia) and pneumonia. Before pneumococcal
conjugate vaccine (PCV) introduction, the incidence of
these IPDs in children aged under 2 years was 44.4/
100,000 per year in Europe and 167/100,000 in the
United States, and only 11 serotypes caused 70% of
them worldwide [1]. In France, the 7‐valent PCV
(PCV7, including 4, 6B, 9V, 14, 18C, 19F and 23F sero-
types) was introduced and recommended in January
2003. In parallel, a nationwide campaign was initiated
to promote better-targeted antibiotic use, which re-
duced prescriptions by 25% over 5 years [2]. On the
one hand, PCV7 led to significantly fewer IPDs due to
vaccine serotypes but was associated with more IPDs
due to non-vaccine serotypes (especially 19A) because
of serotype replacement [3, 4]. On the other hand, the
decreased antibiotic use interfered with vaccine-
induced serotype replacement by favouring penicillin-
susceptible strains (e.g. 7F and 3) probably because of
their higher transmissibility and greater invasiveness
[5]. The interaction between PCV7 introduction and
antibiotic reduction led to important increases of non-
vaccine and penicillin-susceptible strains, resulting in
an overall rise of the number of pneumococcal menin-
gitis (PM) cases [5]. In other neighbouring countries
that introduced PCV7 without lowering antibiotic use,
PCV7 introduction had different effects according to the
country and the age group: in Germany, Switzerland,
England and Wales a substantial reduction in IPDs was
achieved [6–8], while in Spain, the impact of PCV7 was
attenuated by the increase of non-PCV7 serotypes [9].
Despite these differences, some homogeneity concern-
ing emerging serotypes (19A, 7F, 3) was observed [6, 8,
10, 11]. In the US, overall IPD incidence rates in adults
and children declined significantly during the first
3 years of PCV7 use and stabilised thereafter [12, 13].
Nevertheless, PM incidence rates increased among
adults, for which non-PCV7-serotype PM increase was
greater than PCV7-serotype PM reduction [12].
In July 2010, the French High Council for Public Health
recommended replacing PCV7 with the 13-valent PCV13,
which covers six additional serotypes (Delta6: 1, 3, 5, 6A,
7F, 19A). To enlarge PCV coverage further, in December
2013, the 23-valent polysaccharide pneumococcal vaccine
(PPV23; adding 2, 8, 9N, 10A, 11A, 12F, 15B, 17F, 20, 33F)
was also recommended for at-risk children above 6 years
old. Its clinical and serologic responses in at-risk children
above 2 years old were recently evaluated in the US [14].
A higher valency PCV targeting 15 serotypes (adding 22F
and 33F: Delta2) is being evaluated and has shown prom-
ising preclinical results but its production is more com-
plex and costs more [15].
Using time-series analyses, we analysed PM trends in
France from 2001 to 2014. Differences in PM case
numbers were quantified and compared to the pre-
vaccine era for each epidemiological period, for the
total PM series and by age group and serotype class.
Annual numbers and percentages of the main isolated
PCV and non-vaccine serotypes for all the periods con-
sidered were analysed to study their evolution.
Methods
Data sources
PM data for metropolitan France were available from
January 2001 to December 2014 from the French
National Reference Center for Pneumococci (NRCP),
which, since 2001, has received all S. pneumoniae strains
isolated from cerebrospinal fluid (meningitis) collected
through the Observatoires Régionaux du Pneumocoque,
a network of about 400 laboratories located in the 13
French regions (67% of public and private French labora-
tories and around 60% of the French population over the
period considered). Serotyping is performed using latex
particles sensitised with antisera marketed by the Statens
Serum Institute as described in previous publications
[4]. Serotypes 6A and 6C were retrospectively identified
for the 2001–2009 years using the two new respective
factor sera marketed by the Statens Serum Institute in
2010. For each isolate, date of infection, patient’s age,
serotype and penicillin G susceptibility, defined by Mini-
mum Inhibitory Concentration (penicillin-non-suscep-
tible is defined as > 0.06 mg/L) were recorded. Because
the NRCP database is not exhaustive and to assess the
stability of data-system recording, i.e. to ensure that re-
cruitment bias did not evolve over time, we compared
NRCP PM data with those provided by Epibac, a non-
independent national surveillance network, for which a
constant coverage around 74% of the French metro-
politan population since 1999 was proved [16]. From
Epibac, serotype and penicillin G susceptibility of S.
pneumoniae strains was not available. The number of
“flu-like” syndromes was provided by the French Senti-
nelles Network (http://sentiweb.org, accessed: 10
October 2015); demographic data were obtained from
the French National Institute of Statistics and Economic
Studies (http://www.insee.fr, accessed: 2 October 2015). Vac-
cine coverage was provided by Santé Publique France
(http://www.santepubliquefrance.fr/, accessed: 28 September
2016) and community consumption of antibiotics (beta-
lactams and macrolides) expressed in Defined Daily
Dose (DDD) per 1000 inhabitants and per day were
provided by the European Centre for Diseases
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prevention and Control (http://ecdc.europa.eu/en/Pages/
home.aspx, accessed: 28 September 2016).
Statistical analysis
Temporal variations of PM cases were estimated using
time-series analysis through a generalisation of autoregres-
sive–moving-average (ARMA) models (named ARMAX or
intervention-transfer–function model), which allows the
introduction of input variables. We estimated monthly PM
case differences compared to the pre-vaccine era, defined
as January 2001–June 2003, as a vaccination effect during
the 6 months following PCV introduction was deemed un-
realistic because of that lag time. Since PM incidence ex-
hibits seasonality with winter peaks, 12-month periods
were defined starting 1 July of year n and finishing on 30
June of year n + 1, yielding 11 “epidemiological periods”
between July 2003 and June 2014. During the baseline
period, the monthly number of PM cases expected
without any vaccination effect, for a given population
size, was estimated. To take into account demographic
evolution, the monthly number of PM cases was weighted
by the ratio of the mean population size during the base-
line period divided by the year n population size.
Because of seasonal fluctuations, a trigonometric func-
tion had to be estimated and removed to make the series
non-seasonal. Assuming that vaccination did not modify
seasonal fluctuations, i.e. the post baseline PM series
followed the same seasonality as baseline, but affected
only the mean, we removed from the entire series
(2001–2014) a periodic trigonometric function estimated
on the baseline period. We fitted to the non-seasonal
series an ARMAX, including 11 dummy variables repre-
senting each post vaccine epidemiological period and
“flu-like” syndromes incidence, according to previous
findings that suggested an IPD–influenza virus inter-
action [17, 18]. The FLS incidence was added to this
model, using a simple transfer function. To check the
fitness of the model, we first tested the independence of
the residual series (Ljung and Box test) and its Gaussian
distribution (Shapiro–Wilk test). The construction and
the writing of the model were partly described previ-
ously (see Supporting Text S1 in reference [19]).
We quantified the estimated difference in absolute
number and percent change of monthly PM cases for
each epidemiological period versus the corresponding
baseline period, meaning that we calculated the differ-
ence between the estimated number predicted by the
model and the one expected under the assumption of no
change since the baseline period. The same procedure
was applied to following PM groups: PCV7-serotype PM
cases (4, 6B, 9V, 14, 18C, 19F, 23F), PCV13 Delta6-
serotype PM cases (1, 3, 5, 6A, 7F, 19A), other non-
vaccine-serotype PM cases and the two most exposed
age groups (<5 and > 64 years old).
The evolution of serotype distributions was assessed
for the entire population and the two age groups by
computing the frequency of each capsular type of S.
pneumoniae for each epidemiological period.
Analyses were computed with SAS v9.3 (SAS Institute,
http://www.sas.com/) and R 3.1.0. All statistical tests
were two-tailed and P < 0.05 defined significance.
Results
Vaccine coverage
After PCV7 introduction, the vaccine coverage was ini-
tially modest (56% of children vaccinated at 24 months
in the 2004 birth cohort), but gradually increased to 83%
in 2006. The vaccine coverage was 94% when PCV7 was
replaced by PCV13 in 2010, and remained stable until
the end of the study period (Fig. 1).
Antibiotic consumption
Community consumption of beta-lactams and macro-
lides averaged 21.23 DDD per inhabitant per day during
the baseline period (2001–2003). The national campaign
initiated to promote better-targeted antibiotic use led to
a marked decline in the consumption of these two anti-
biotic classes, with 16.27 DDD per inhabitant per day in
2004. Community consumption then plateaued until
2010, before it started increasing to reach 20.11 DDD
per inhabitants per day in 2014 (Fig. 1).
Between January 2001 and December 2014, 6025 and
5166 PM cases were recorded in the Epibac and NRCP
databases, respectively. In accordance with that stated by
Lepoutre et al. [16], comparisons between Epibac and
NRCP PM cases enabled us to confidently conduct
time-series analyses of NRCP data. Indeed, the compari-
son with Epibac data indicated stable reporting fidelity
of the NRCP surveillance system (regression slope –0.82
(CI), P = 0.32). An ARMAX model fulfilling goodness-
of-fit criteria was obtained for each series, enabling
reliable interpretation of the estimations (Fig. 2, for all se-
rotypes and age series, and Additional file 1: Figure S1 for
age-class series).
PM cases in the entire population
Results for model-estimated deviations are reported in
Table 1 and relative PM percent changes in Fig. 3.
All serotypes
Total PM numbers were globally stable over time, except
for the epidemiological periods in 2008–2009 and 2009–
2010, when they increased significantly by 22% (95% CI,
9.0 to 34.4) and 18% (95% CI, 5.2 to 31.2), respectively.
Thereafter, PM numbers returned to the baseline level
until 2013–2014, when they finally decreased by –7.1
per month (95% CI, –10.8 to –3.35) compared to the
pre-vaccine era.
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PCV7 serotypes
The monthly numbers of PCV7-serotype PM cases declined
gradually from 2004–2005 until 2009–2010 (when they
reached their maximum diminution of –86% (95% CI, –92.1
to –79.0) from baseline) and remained stable thereafter, at an
estimated average of 2 PCV7-PMcases permonth.
Delta6 serotypes
The number of PM cases due to the PCV13 Delta6
started to increase significantly in 2006–2007, reaching a
maximum of almost 15 (95% CI, 13.2 to 16.3) PM cases
(baseline + period deviation) per month in 2008–2009,
nearly three times the number expected. Their number
began to decline the following year, with a statistically sig-
nificant 43% (95% CI, –71.1 to –14.7) reduction from
baseline in 2012–2013 that remained stable in 2013–2014.
Non-vaccine serotypes
The monthly numbers of non-vaccine serotype PM cases
have risen significantly since 2006–2007. After having
Fig. 1 Antibiotic consumption in number of defined daily dose per inhabitants and per day and percentage pneumococcal conjugate vaccine
(PCV) coverage. Squares are beta-lactams and macrolides consumption in the community (primary care sector) and dots are PCV coverage
percent for primary immunisation at 24 months of age in France from 2000 to 2014
Fig. 2 Total monthly pneumococcal meningitis (PM; grey), ARMAX model predictions (red) and estimated percent changes, 2001–2014. Grey lines
are the numbers of expected PM cases during epidemiological periods under the assumption of no change compared to the baseline period
(2001–2003). Red lines are the model-estimated PM numbers during epidemiological periods. The percentages indicated above the curves are
significant relative changes compared to baseline. NS: nonsignificant. *Stable population
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increased almost two-fold in 2010–2011 from the base-
line, they stabilised thereafter. The 2013–2014 dimin-
ution of the increase did not differ significantly from the
previous year (+8.8; 95% CI, 6.68 to 10.88 vs. +11.3; 95%
CI, 9.30 to 13.30 in 2012–2013).
PM cases among age groups
Children under 5 years old
PM cases number trends among children younger than
5 years old were similar to those observed for the overall
population. After an estimated rise of almost +2 (95%
CI, 0.31 to 3.05) cases/month in 2008–2009, total PM
number for children under 5 years started to decrease in
2011–2012 and displayed a reduction of 43% (95% CI, –
60.0 to –25.5) in 2013–2014 (Table 2 and Fig. 4). PCV7-
serotype PM cases began to decrease in 2004–2005 and
they have almost been eradicated since 2007–2008. The
number of PCV13-serotype PM cases rose between 2008
and 2010 but decreased thereafter and returned to pre-
vaccine era numbers. Non-vaccine serotype PM cases
Table 1 Model-estimated deviationsa between numbers of monthly pneumococcal meningitis (PM) cases, according to serotype
and compared to baseline
Epidemiological number of PM cases per month
Period PCV7 Serotype P valueb Delta6 Serotypec P value Non-vaccine Serotype P value Total P value
Baselined 15.3 – 5.5 – 7.5 – 28.2 –
2003–2004 –0.1 (–0.66 to 0.78) 0.87 +0.2 (–1.22 to 1.65) 0.77 –0.9 (–2.64 to 0.90) 0.33 –1.3 (–3.87 to 1.22) 0.30
2004–2005 –2.4 (–3.17 to –1.70) <0.001 +0.9 (–0.61 to 2.41) 0.24 +3.7 (1.88 to 5.50) <0.001 +3.9 (0.69 to 7.15) 0.017
2005–2006 –4.0 (–4.89 to –3.06) <0.001 +1.4 (–0.10 to 2.86) 0.07 +1.5 (–0.41 to 3.39) 0.12 –1.9 (–5.36 to 1.62) 0.29
2006–2007 –6.4 (–7.29 to –5.48) <0.001 +4.4 (2.86 to 5.89) <0.001 +3.4 (1.50 to 5.27) <0.001 +2.5 (–1.06 to 5.98) 0.17
2007–2008 –8.0 (–9.01 to –7.09) <0.001 +2.7 (1.19 to 4.28) <0.001 +5.0 (3.13 to 6.94) <0.001 0.7 (–2.82 to 4.33) 0.68
2008–2009 –11.0 (–11.99 to –10.05) <0.001 +9.2 (7.76 to 10.79) <0.001 +9.0 (7.11 to 11.00) <0.001 +6.1 (2.55 to 9.70) <0.001
2009–2010 –13.1 (–14.11 to –12.09) <0.001 +5.4 (3.80 to 6.94) <0.001 +9.6 (7.65 to 11.61) <0.001 +5.2 (1.47 to 8.79) 0.006
2010–2011 –12.6 (–13.58 to –11.66) <0.001 +3.6 (2.15 to 5.11) <0.001 +13.6 (11.74 to 15.56) <0.001 +2.9 (–0.66 to 6.44) 0.11
2011–2012 –12.9 (–13.88 to –11.94) <0.001 +1.3 (–0.18 to 2.77) 0.08 +11.2 (9.21 to 13.11) <0.001 +1.1 (–2.46 to 4.72) 0.53
2012–2013 –12.8 (–13.87 to –11.79) <0.001 –2.4 (–3.91 to –0.81) 0.003 +11.3 (9.30 to 13.30) <0.001 –3.2 (–6.85 to 0.47) 0.08
2013–2014 –13.7 (–14.85 to –12.54) <0.001 –1.6 (–3.08 to –0.06) 0.041 +8.8 (6.68 to 10.88) <0.001 –7.1 (–10.85 to –3.35) <0.001
aThe number of PM cases/month predicted by the model for a fixed population size without vaccination. Estimates were adjusted to flu-like syndrome frequency,
for each 12-month period from 1 July to 30 June, followed by their 95% confidence interval
bP values are for the comparison of each epidemiologic period’s value versus baseline
cDelta6 refers to the six serotypes added to PCV7 to obtain PCV13
dBaseline values are expected PM cases per month
Fig. 3 Estimated percent changes compared to the baseline period (2001–2003) during epidemiological periods. Total pneumococcal meningitis
cases (black), PCV7 (blue), the six added to PCV7 to obtain PCV13 (yellow) and non-vaccine (red) serotypes
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significantly increased since 2007–2008 and until 2012–
2013, when they reached their maximum growth of
+3.9 PM cases (95% CI, 3.31 to 4.54) per month. This in-
crease was significantly minor in 2013–2014 (+1.7; 95%
CI, 1.09 to 2.37 vs. +3.9; 95% CI, 3.31 to 4.54 in 2012–
2013, P = 0.01).
Adults above 64 years old
For total PM cases among individuals above 64 years
old, a significant monthly PM reduction of –2.0 (95% CI,
–3.36 to –0.57) was estimated in 2013–2014 (Table 3
and Additional file 1: Figure S2). The number of PCV7-
serotype PM cases reached its maximum diminution in
2009–2010 (–2.8 PM cases; 95% CI, –3.39 to –2.28).
After steadily increasing until 2009–2010, the number of
PCV13-serotype PM cases successively declined (–87%;
95% CI, –152.5 to –21.5) since 2012–2013. The non-
vaccine serotype PM cases reached their maximum
increase in 2011–2012 (+4.5; 95% CI, 3.64 to 5.36) and
then stabilised.
Table 2 Model-estimated deviationsa between monthly numbers of pneumococcal meningitis (PM) cases in children under 5 years
old, compared to baseline
Epidemiological Number of PM cases per month
Period PCV7 serotype P valueb Delta6 serotypec P value Non-vaccine serotype P value Total P value
Baselined 5.5 – 1.6 – 0.8 – 8.0 –
2003–2004 +0.2 (–0.26 to 0.67) 0.39 –0.1 (–0.76 to 0.56) 0.76 –1.2 (–1.74 to –0.65) <0.001 +1.3 (–0.02 to 2.70) 0.05
2004–2005 –1.2 (–1.69 to –0.75) <0.001 +0.3 (–0.36 to 0.97) 0.37 +0.8 (0.23 to 1.42) 0.007 +1.0 (–0.39 to 2.36) 0.16
2005–2006 –3.0 (–3.51 to –2.59) <0.001 +0.1 (–0.54 to 0.78) 0.72 +0.3 (–0.26 to 0.91) 0.28 –1.1 (–2.47 to 0.20) 0.09
2006–2007 –3.2 (–3.64 to 2.70) <0.001 +1.5 (0.84 to 2.16) <0.001 +0.3 (–0.22 to 0.93) 0.23 +0.2 (1.11 to 1.58) 0.73
2007–2008 –4.2 (–4.64 to –3.71) <0.001 +0.4 (–0.26 to 1.07) 0.23 +1.2 (0.61 to 1.77) <0.001 –1.0 (–2.38 to 0.32) 0.14
2008–2009 –5.1 (–5.56 to –4.56) <0.001 +1.8 (1.14 to 2.49) <0.001 +1.0 (0.42 to 1.65) <0.001 +1.7 (0.31 to 3.05) 0.016
2009–2010 –4.6 (–5.14 to –4.15) <0.001 +1.5 (0.82 to 2.19) <0.001 +2.0 (1.44 to 2.65) <0.001 +1.0 (–0.34 to 2.45) 0.13
2010–2011 –4.8 (–5.27 to –4.35) <0.001 +0.7 (0.01 to 1.34) 0.045 +3.3 (2.74 to 3.92) <0.001 –0.6 (–1.93 to 0.75) 0.38
2011–2012 –5.4 (–5.82 to –4.90) <0.001 +0.5 (–0.15 to 1.16) 0.13 +2.1 (1.56 to 2.71) <0.001 –1.6 (–2.92 to –0.26) 0.019
2012–2013 –4.7 (–5.24 to –4.21) <0.001 –0.3 (–1.04 to 0.33) 0.31 +3.9 (3.31 to 4.54) <0.001 –2.7 (–4.14 to –1.36) <0.001
2013–2014 –5.2 (–5.71 to –4.62) <0.001 –0.3 (–0.93 to 0.39) 0.42 +1.7 (1.09 to 2.37) <0.001 –3.5 (–4.81 to –2.13) <0.001
aThe number of PM cases/month predicted by the model for a fixed population size without vaccination. Estimates were adjusted to flu-like syndrome frequency,
for each 12-month period from 1 July to 30 June, followed by their 95% confidence interval
bP values are for the comparison of each period’s value versus baseline
cDelta6 refers to the six serotypes added to PCV7 to obtain PCV13
dBaseline values are the numbers of expected PM cases per month
Fig. 4 Estimated pneumococcal meningitis (PM) cases percent changes compared to baseline (2001–2003) for children under 5 years old. Total
PM cases (black), PCV7 (blue), the six added to PCV7 to obtain PCV13 (yellow) and non-vaccine (red) serotypes
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Change of serotype distributions
Before the vaccine (2001–2003), PCV7 serotypes were
the most frequent (53% of total PM cases) and they were
principally penicillin-non-susceptible (Fig. 5). After
PCV7 introduction, serotypes 19A, 7F and 3 became
dominant, while 12F, 23B, 24F and 35B significantly
emerged, with rankings increased by at least 10 positions
within the serotype pattern, regardless of penicillin sus-
ceptibility. In 2012–2014, 4 years after introducing
PCV13, other serotypes appeared in the top serotype-
distribution ranks. Among non-vaccine serotypes, 12F
became dominant (from 2% of PM cases in 2007–2009
to 8%), while the emerging 24F serotype confirmed its
position among the most recurrent non-vaccine sero-
types, and serotypes 23B, 10A, 15A and 6C clearly be-
came more widespread. The second most common
serotypes 3 and 19A, both included in the PCV13,
remained relatively high even after its introduction (8%
and 6% of the total PM cases, respectively). Surprisingly,
PCV7-serotype 19F rose again after its first post-PCV7
reduction and became the third most frequent serotype
(and first among the penicillin-resistant serotypes) in
2012–2014. Delta2-serotypes 22F and 33F, which are ex-
pected to be added to the future possible PCV15,
accounted for only 5% and 2%, respectively, of the total
serotypes isolated in 2012–2014. Percentages and num-
bers of the main serotypes isolated from PM cases are
shown in Additional file 1: Table S1.
For children under 5 years old (Fig. 6), PCV13 intro-
duction led to the remarkable dominance of non-
vaccine serotypes, with 24F, 10A, 12F and 15A
responsible for approximately 39% of the PM cases in
2012–2014. Vaccine serotype 3 was rare (2%), while the
PCV15 Delta2-serotypes 33F and 22F represented 5%
and 4%, respectively, of this age group’s total PM cases.
For adults above 64 years old (Additional file 1: Figure S3),
serotype 6C showed the most remarkable rising to the
dominant rank in 2012–2014 (10% of PM cases). Non-
vaccine serotypes 23B (9%) and 24F (6%) and vaccine
serotypes 19F (8%), 3 (7%) and 7F (6%) were the most
frequently observed in this age group during 2012–
2014. The PCV15 Delta2-serotypes accounted for 6%
(22F) and 3% (33F) of the total PM cases.
Discussion
The first evident benefit of the cumulative effects of
PCV7 and PCV13 on the entire French population ap-
peared 11 years after the former’s introduction, with a
significant 25% decrease of the total PM cases. We did
not observe population-wide reductions in total PM
numbers following PCV7 introduction, although
vaccine-specific serotypes did reduce. In contrast, fol-
lowing PCV13 introduction in 2010, a reduction of
25% in all PM numbers in the population was observed
in 2013–2014. We confirmed the positive PCV7 im-
pact on young children and its herd-immunity effect
on the entire population, as well as partial serotype-
replacement phenomena. The significant increase ob-
served in 2008–2009 (caused by nonPCV7 serotypes)
for total PM cases suggested that PCV7 benefits were
quickly overtaken by serotype replacement, among
others (see below). During the following periods,
Table 3 Model-estimated deviationsa between monthly numbers of pneumococcal meningitis (PM) cases in adults above 64 years
old, compared to baseline
Epidemiological Number of PM cases per month
Period PCV7 serotype P valueb Delta6 serotypec P value Non-vaccine serotype P value Total P value
Baselined 3.7 – 1.3 – 2.0 – 6.7 –
2003–2004 –0.03 (–0.50 to 0.44) 0.89 +0.3 (–0.51 to 1.19) 0.43 +1.2 (0.34 to 2.03) 0.006 –1.2 (–2.60 to 0.18) 0.09
2004–2005 –0.2 (–0.75 to 0.26) 0.35 +0.5 (–0.35 to 1.41) 0.24 +1.8 (0.94 to 2.62) <0.001 +0.6 (–0.82 to 2.00) 0.41
2005–2006 –0.6 (–1.18 to –0.10) 0.021 +0.5 (–0.30 to 1.40) 0.20 +1.6 (0.73 to 2.44) <0.001 –0.4 (–1.79 to 1.01) 0.58
2006–2007 –0.1 (–0.68 to 0.40) 0.60 +1.3 (0.49 to 2.19) 0.002 +2.1 (1.23 to 2.93) <0.001 +1.5 (0.16 to 2.95) 0.03
2007–2008 –0.9 (–1.47 to –0.39) <0.001 +1.1 (0.28 to 2.00) 0.009 +2.4 (1.50 to 3.23) <0.001 +0.3 (–1.11 to 1.69) 0.68
2008–2009 –1.5 (–2.06 to –0.93) <0.001 +3.7 (2.83 to 4.55) <0.001 +3.3 (2.41 to 4.18) <0.001 +1.3 (–0.07 to 2.77) 0.06
2009–2010 –2.8 (–3.39 to –2.28) <0.001 +2.7 (1.81 to 3.56) <0.001 +3.1 (2.23 to 4.02) <0.001 +0.3 (–1.14 to 1.71) 0.69
2010–2011 –3.1 (–3.59 to –2.52) <0.001 +0.7 (–0.18 to 1.54) 0.12 +3.6 (2.74 to 4.45) <0.001 +0.6 (–0.66 to 6.44) 0.11
2011–2012 –2.2 (–2.78 to –1.73) <0.001 –0.4 (–1.26 to 0.45) 0.35 +4.5 (3.64 to 5.36) <0.001 +0.5 (–0.84 to 1.93) 0.43
2012–2013 –2.7 (–3.28 to –2.15) <0.001 –1.2 (–2.03 to –0.29) 0.009 +3.3 (2.42 to 4.20) <0.001 +0.5 (–0.92 to 1.94) 0.48
2013–2014 –3.1 (–3.70 to –2.47) <0.001 –1.1 (–1.96 to –0.25) 0.010 +2.8 (1.98 to 3.73) <0.001 –2.0 (–3.36 to –0.57) 0.006
a The number of PM cases/month predicted by the model for a fixed population size without vaccination. Estimates were adjusted to flu-like syndrome frequency,
for each 12-month period from 1 July to 30 June, followed by their 95% confidence interval
b P values are for the comparison of each period’s value versus baseline
c Delta6 refers to the six serotypes added to PCV7 to obtain PCV13
d Baseline values are the numbers of expected PM cases per month
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PCV13 effectively offset this augmentation, despite
non-vaccine-serotype reinforcement, which counterba-
lanced and attenuated the PCV13 diminution effect on
total PM cases. This decline was already evident in
2011–2012 for children under 5 years, in accordance
with previous studies [16, 20]. Furthermore, adults
above 64 years old also benefited from herd immunity
[21].
The reasons for the long delay between the first PCV
introduction and effective reduction of total PM num-
bers, and why a second vaccine (PCV13) was necessary
to remedy the consequences of the first, could be differ-
ent. When PCV7 was introduced in 2003, the proportion
of PM cases caused by its serotypes in the French popu-
lation was lower than in other countries [22] and its
coverage was only 56% in children born in 2004 [16]. In
contrast, PCV13 composition included the most virulent
serotypes in the postPCV7 period and PCV coverage
was above 90%. Other factors, like antibiotic consump-
tion or natural pneumococcal ecologic evolution, could
also have had different and unexpected consequences on
PM evolution. During the PCV7 immunisation period,
antibiotic consumption decreased, whereas it remained
stable during PCV13 introduction. These circumstances
could explain the prolonged interval required to achieve
effective PM diminution.
Although PCV13 use outcome has been positive, its
impact on some vaccine serotypes remains controver-
sial. As for other high-income countries that intro-
duced PCV13 [6, 7, 23–25], in France, serotype 3
remained among the most frequent in older adults
4 years after PCV13 introduction, probably because of
the absence of herd protection for this penicillin-
susceptible serotype, which is rare in young children
more frequently exposed to antibiotic consumption
[26]. A recent study of the impact of PCV13 on PM
cases in US children 3 years following vaccine intro-
duction revealed that PM case numbers remain un-
changed in the study sample and serotype 19A
continued to be the most common serotype [27]. In
our study, we observed a decrease of serotype 19A only
in 2012–2013 in France. For this serotype the expected
cross-protection from PCV7 because of the inclusion
of the serogroup 19 by serotype 19F was limited and a
delayed effect of the vaccine on this intrinsically more
epidemic serotype, which was still in full expansion
when the vaccine was introduced, was also reported in
other countries [6, 28]. In the last few years, a resur-
gence of PCV7-serotype 19F was also observed, making
it the most frequent serotype responsible for PCV7
failure in France [29]. This penicillin-resistant serotype
might have been driven by high antibiotic exposure
Fig. 5 Numbers of pneumococcal meningitis according to serotype and penicillin susceptibility. PSSP denotes penicillin-susceptible Streptococcus
pneumoniae and PNSP penicillin-non-susceptible Streptococcus pneumoniae
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and vaccine-induced antibodies weaker than for the
remaining serotypes [30].
Post PCV13 serotype replacement was highly variable
across countries: in England and Wales an important in-
crease of IPD due to non-PCV13-serotypes was ob-
served (especially in children under 5 years old) [31]; in
contrast, in other countries, such as Denmark, Spain,
and the US, serotype replacement was limited, so that an
overall decrease in IPD incidence was observed after the
introduction of PCV13 [23, 25, 32]. In France, PCV13
favoured the emergence of other new emerging sero-
types not included in the vaccine [16]. Our analysis of
serotype distributions demonstrated that 12F, 24F, 23B
and 10A were the most frequent non-vaccine serotypes
that emerged in the entire French population during the
post-PCV13 period. Serotype 12F reached the dominant
position in 2011–2013 for the entire population and for
children under 5 years old, thereby confirming earlier
findings in France [33, 34] and other countries reporting
its outbreak or hyperinvasivity [35–38]; its highly inva-
sive disease potential was also recently shown in France
for children under 2 years old [39]. With the same ele-
vated invasive disease potential as 12F, we reported sero-
type 24F emergence in France [39], as in many other
European countries [6, 40]. Despite the expected cross-
protection between 6C and PCV13-serotype 6A [24, 41],
we confirm a marked expansion of serotype 6C among
adults above 64 years, previously observed in France
[42] and other countries [6, 31].
Several limitations of this study should be noted.
Due to the absence of a control group and limited pre-
intervention data, a cause–effect relationship between
the PCV introduction and PM evolution cannot be
proved. Even though non-vaccine serotypes became
dominant, other vaccine serotypes remained frequent,
so vaccine impact cannot completely explain serotype
evolution. Other factors, like specific natural competi-
tion, vaccination-induced cross-immunity, serotype-
specific intrinsic epidemicity or periodic trend in
serotype-colonisation turnover cannot be excluded
[11, 25, 43, 44]. Furthermore, the selection of circulat-
ing pneumococcal strains can also be influenced by
antibiotic exposure, which can interfere with the
vaccine-induced serotype replacement. The lower in-
trinsic epidemic fitness of resistant pneumococcal
strains [45] could explain why the antibiotic-
susceptible strains are disadvantaged in a context of
high level of antibiotic exposure but become more epi-
demic than resistant strains when antibiotic use
declined. In France, the National campaign “Keep anti-
biotics working” led to a decrease of antibiotic expos-
ure by at least 25% [2], the highest diminution among
Fig. 6 Number of pneumococcal meningitis (PM) cases occurring in children under 5 years old according to serotype and penicillin susceptibility.
PSSP denotes penicillin-susceptible Streptococcus pneumoniae and PNSP denotes penicillin-resistant Streptococcus pneumoniae
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the developed nations, which has been suggested to
have an impact on the incidence of severe infections
caused by non-vaccine antibiotic-susceptible pneumo-
coccal strains [5]. Because of lack of monthly data, we
did not include antibiotic consumption series in our
model.
Conclusions
Vaccine preventable diseases like IPD require the devel-
opment of an efficient surveillance system to monitor
pre- and post-vaccination trends. In countries that have
just introduced a new vaccine, the assessing of its impact
is possible only if surveillance data had been collected
both before and after vaccine introduction. Only an ex-
cellent surveillance system can allow to asses vaccine
impact and therefore set up a future immunisation pol-
icy adequately. In countries with a settled immunisation
program, because of the rapid ecologic modifications
that we observed also in our analysis, a highly reactive
surveillance system focusing on infections and colonisa-
tion is required. Public health decision-makers should be
aware of the continuous evolution of the local PM epi-
demiology and they should demand that manufacturers
rapidly adapt vaccines to the target population. Our
study results highlight the emergence in France of a
group of non-vaccine serotypes very different from
those emerging in the US, especially among young chil-
dren [27]. Despite the PCV15 vaccine covering an add-
itional 21% of IPD cases among children in the US [23],
in France, where 22F and 33F accounted for only 9% of
PM cases in 2012–2014, this vaccine is not useful. If
the observed non-vaccine serotype emergence con-
tinues a different formulation of a higher valent vaccine
will be required.
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